In patients with SLE, the use of AMA has been associated with a wide variety of beneficial effects [54,55], including favourable associations with biological disease properties such as lower levels of B cell activating factor (BAFF) [56] and favourable effects on HRQoL [57]; this drug class constitutes the cornerstone of SLE therapy. Here, TNFSF13B is linked to systemic lupus erythematosus.